CytoSorbents Corporation Aktie News

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Makis Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing Christ...

Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSW...

PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024.

PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor...

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript

STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales increased approximately 10% year-over-year    2023 Product gross margins increased to 72%    Cumulat...

PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT.

PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44 th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA o...